Insights from 2024 EHA Annual Meeting


 

EHA 2024 Insights: SYMPATICO Study - Ibrutinib + Venetoclax in MCL With TP53 Mutations

43 views
June 30, 2024
Comments 0
Login to view comments. Click here to Login